N
Nempathy
Performance Authority

Trade investment you can prove.

Trade spend is the second-largest line on a CPG P&L after cost of goods — and between 8% and 12% of it leaks through inaccurate accruals, unmatched deductions, and promotions whose return nobody can substantiate. Recovery goes straight to EBITDA.

Under tariffs and ingredient inflation, price increases are landing more often and larger. Every announcement opens a forward-buy window, and every window is another accrual nobody documented. The question on each one is the same: could the person who signed it prove it, or only repeat it?
Working demonstrations
The interactive tool

Commercial Performance Index™

Fifteen questions across the five pillars. Put in their revenue, work through it with them in the room, and it returns a score, a pillar-by-pillar heat map, the two areas to attack first, and an EBITDA opportunity sized to their own business — with every assumption stated on screen.

Run the diagnostic →
Prospect-specific

Thermos — Tariff & Forward Buy

What the April 6, 2026 Section 232 change does to a stainless-steel product line: the duty basis moved from metal content to full customs value, so the same rate costs multiples of what it did. Model the landed-cost shock live, and see why it forces a price increase — which opens the window.

Open the model →
Start here

Forward Buy Exposure

A tariff-driven price increase opens a 90-day window. Retailers load at the old price. Ninety days later the deductions arrive on a basis nobody documented. Shows the shipment whipsaw, five claims matched against the commitment on record — and one that cannot be proven either way.

Open the demonstration →

Trade Promotion Audit

Deduction-level view across five retailers: what was committed, what was claimed, what the variance is, and the ledger evidence behind each dispute. Includes a recovery model you can move with the leakage and recovery-rate assumptions.

Open the demonstration →

Portfolio EBITDA Impact

What trade recovery is worth across a private-equity portfolio — company by company, with conservative, realistic, and aggressive scenarios carried through to enterprise value at exit multiple.

Open the model →

OGSM Platform — How to Use

The walkthrough for the diagnostic: what to do in each phase, what to say across the table, and how to close into a working session. Written for the room, not for the file.

Open the guide →
All figures shown are illustrative fixture data built on fictional companies — they demonstrate the mechanism, not any client's results. Where a commitment cannot be substantiated, these tools report it as unprovable rather than clean or fraudulent. Refusing to assert what cannot be grounded is deliberate, and it is the point.